{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:10Z","timestamp":1791402310693,"version":"4.3.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Posaconazole prophylaxis is effective in decreasing the incidence of invasive fungal diseases (IFDs) in patients with acute myeloid leukemia (AML). However, the use of antifungal prophylaxis varies in real-life practice, and only a small number of studies have compared the incidence of IFDs between those receiving posaconazole prophylaxis and those without prophylaxis. We compared the clinical characteristics and outcomes of IFDs between patients with AML who received posaconazole prophylaxis and those without antifungal prophylaxis.<\/jats:p>\n            <jats:p>We reviewed the medical records of adult AML patients who underwent induction chemotherapy between June 2016 and October 2019 at Asan Medical Center (Seoul, South Korea), where posaconazole prophylaxis is not administered in patients with gastrointestinal symptoms that may hinder sufficient absorption of oral prophylactic agents, and in patients with abnormal liver functions considering the possible exacerbation of adverse events. Patients who received posaconazole prophylaxis for \u22657 days were included in the prophylaxis group. Clinical characteristics and outcomes including the incidence of IFDs were compared between the 2 groups.<\/jats:p>\n            <jats:p>Of the 247 patients with AML who underwent induction chemotherapy, 162 (66%) received posaconazole prophylaxis and 85 (34%) did not receive any prophylaxis. The incidence of proven\/probable IFD was significantly higher in the no prophylaxis group than in the prophylaxis group (9.4% [8\/85] vs 2.5% [4\/162], <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03). Of the 8 cases of IFDs in the no prophylaxis group, 7 were mold infections and 1 was invasive candidiasis. Of the 4 cases of IFDs in the prophylaxis group, 3 were mold infections and 1 was invasive candidiasis. Patients with posaconazole prophylaxis less frequently received therapeutic antifungal therapy (2.5% vs 9.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03) and had a longer median, duration from chemotherapy to antifungal therapy compared with the no prophylaxis group (18 vs 11 days, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01). The rate of IFD-related mortality was similar between the 2 groups (0.6% vs 0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.99).<\/jats:p>\n            <jats:p>Patients with AML who received posaconazole prophylaxis had a lower incidence of breakthrough IFDs compared with those who did not receive any prophylaxis. Invasive mold infection was the most common IFD regardless of antifungal prophylaxis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025448","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:02:20Z","timestamp":1621350140000},"page":"e25448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis"],"prefix":"10.1097","volume":"100","author":[{"given":"Eunmi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases"},{"name":"Present affiliation: Department of Infectious Diseases, Seoul Medical Center, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ji","family":"Choi","sequence":"additional","affiliation":[{"name":"Hematology, Asan Medical Center, University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Seung","family":"Park","sequence":"additional","affiliation":[{"name":"Hematology, Asan Medical Center, University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Oh","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Hematology, Asan Medical Center, University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Hematology, Asan Medical Center, University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoo-Hyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Hematology, Asan Medical Center, University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Han","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"R1-20250504","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy","volume":"28","author":"Rotstein","year":"1999","journal-title":"Canadian Fluconazole Prophylaxis Study Group Clin Infect Dis"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/21.2.361","article-title":"Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen","volume":"21","author":"Bow","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3324\/haematol.2010.030825","article-title":"Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study","volume":"96","author":"Even","year":"2011","journal-title":"Haematologica"},{"key":"R6-20250504","first-page":"681","article-title":"Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole","volume":"49","author":"Michallet","year":"2011","journal-title":"Med Mycol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-20250504","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/myc.12086","article-title":"Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients","volume":"56","author":"Peterson","year":"2013","journal-title":"Mycoses"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/myc.12357","article-title":"Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations","volume":"58","author":"Cho","year":"2015","journal-title":"Mycoses"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/myc.12213","article-title":"Our 2014 approach to breakthrough invasive fungal infections","volume":"57","author":"Maschmeyer","year":"2014","journal-title":"Mycoses"},{"issue":"(Suppl 1)","key":"R18-20250504","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3947\/ic.2015.47.1.49","article-title":"Fatal breakthrough mucormycosis in an acute myelogenous leukemia patient while on posaconazole prophylaxis","volume":"47","author":"Kang","year":"2015","journal-title":"Infect Chemother"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/myc.12203","article-title":"Our 2014 approach to mucormycosis","volume":"57","author":"Tacke","year":"2014","journal-title":"Mycoses"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00581-15","article-title":"Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies","volume":"59","author":"Cumpston","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.00496-15","article-title":"Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet vs the oral suspension","volume":"59","author":"Durani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:21:34Z","timestamp":1746339694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025448"}},"subtitle":["A single-center, observational, case-control study in South Korea"],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":28,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025448","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"2020-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}